Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial

Fig. 1

a CONSORT flow diagram. A total of 212 patients were assessed for eligibility, of which 43 were selected for further verification of the eligibility criteria. Finally, 21 participants were selected and randomly assigned to either the mesenchymal stem cell (MSC) or placebo group. The participants were followed for one year and then analyzed for study outcomes. b Schematic description of the study. The process of this clinical trial is generally divided into three main steps, including Patient allocation, MSC preparation, and Monitoring and Follow up. Briefly, selected patients gave informed consent, and after checking full eligibility criteria, they were randomly allocated to either receive MSC or Placebo. Then patients who underwent the first evaluation were subjected to bone marrow aspiration. MSCs were isolated from harvested bone marrow and expanded via culturing in a cleanroom facility. The cells that passed quality-control tests were intravenously injected into group A (early transplantation), while patients in group B received normal saline as a placebo. All patients were followed up for one year, and then the patients in group A received a placebo, whereas patients in group B received MSC (late transplantation). Data were analyzed after 12 and 24 months of follow-up

Back to article page